Umifenovir-d6 is intended for use as an internal standard for the quantification of umifenovir by GC- or LC-MS. Umifenovir is a broad-spectrum antiviral agent.1 It inhibits the replication of H5N1 influenza (IC50 = 30 µg/ml) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro (IC50 = 3.537 µM).1,2 Umifenovir inhibits entry of hepatitis C virus (HCV) pseudoparticles in Huh7 cells (IC50 = 6 µg/ml) and inhibits Zika virus protein synthesis in Vero cells.1,3 In vivo, umifenovir (45 mg/kg) reduces the formation of influenza-induced lung lesions in ferrets.4
1.Boriskin, Y.S., Leneva, I.A., PÉcheur, E.I., et al.Arbidol: A broad-spectrum antiviral compound that blocks viral fusionCurr. Med. Chem.15(10)997-1005(2008) 2.Pizzorno, A., Padey, B., Dubois, J., et al.In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2Antiviral Res.181104878(2020) 3.Fink, S.L., Vojtech, L., Wagoner, J., et al.The antiviral drug arbidol inhibits Zika virusSci. Rep.8(1)8989(2018) 4.Wang, Y., Ding, Y., Yang, C., et al.Inhibition of the infectivity and inflammatory response of influenza virus by Arbidol hydrochloride in vitro and in vivo (mice and ferret)Biomed. Pharmacother.91393-401(2017)